1 unchanged sentence
Evaluation of disclosure controls and procedures.
−Removed: We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
+Added: We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.
2 unchanged sentences
The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
−Removed: Based on their evaluation as of the end of the period covered by this Annual Report on Form 10-K, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
+Added: Based on their evaluation as of the end of the period covered by this Annual Report on Form 10-K, our Chief Executive Officer and Principal Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in internal control over financial reporting.
4 unchanged sentences
Projections of any evaluation of the effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
−Removed: Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework).
−Removed: Based on our evaluation under the framework in Internal Control—Integrated Framework , our management concluded that our internal control over financial reporting was effective as of December 31, 2024.
+Added: Our management, with the participation of our Chief Executive Officer and Principal Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework).
+Added: Based on our evaluation under this framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2025.
The effectiveness of our internal control over financial reporting as of December 31, 2025 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.
4 unchanged sentences
In our opinion, Incyte Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on the COSO criteria.
−Removed: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and our report dated February 10, 2025 expressed an unqualified opinion thereon.
+Added: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes and our report dated February 10, 2026 expressed an unqualified opinion thereon.
Basis for Opinion
18 unchanged sentences
Other Information
−Removed: (b) During the three months ended December 31, 2024, the following officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted a prearranged trading plan relating to our common stock and intended to satisfy the affirmative defense of Rule 10b5–1(c) under the Securities Exchange Act of 1934.
−Removed: Christiana Stamoulis , our Executive Vice President and Chief Financial Officer , adopted a trading plan on November 26, 2024 providing for the sale of up to an aggregate of 107,938 shares of our common stock until November 26, 2025 .
−Removed: Sheila Denton , our Executive Vice President and General Counsel , adopted a trading plan on November 27, 2024 providing for the sale of up to an aggregate of 32,014 shares of our common stock until November 27, 2025 .
−Removed: Barry Flannelly , our Executive Vice President and General Manager, North America , adopted a trading plan on December 13, 2024 providing for the sale of up to an aggregate of 315,415 shares of our common stock until January 6, 2026 .
+Added: (a) On February 6, 2026, we entered into a registration rights agreement (the “Registration Rights Agreement”) with 667, L.P.
+Added: and Baker Brothers Life Sciences, L.P.
+Added: (the “Baker Entities”), both of which are existing stockholders of our company and are affiliated with the Chairman of our Board of Directors, Julian C.
+Added: The Registration Rights Agreement replaces the registration rights agreement we entered into with the Baker Entities in February 2016 that continued in effect for 10 years.
+Added: Under the Registration Rights Agreement, we agreed that, if requested by the Baker Entities, we would register our securities held by the Baker Entities for resale under the Securities Act of 1933.
+Added: Our registration obligations under the Registration Rights Agreement cover all of our securities now held or later acquired by the Baker Entities, will continue in effect for up to 10 years, and include our obligation to facilitate certain underwritten public offerings of our securities by the Baker Entities in the future.
+Added: The Registration Rights Agreement is filed as Exhibit 10.25 to this report and the description of the terms of the Registration Rights Agreement is qualified in its entirety by reference to such exhibit.
+Added: (b) During the three months ended December 31, 2025, the following officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted a prearranged trading plan relating to our common stock and intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) under the Securities Exchange Act of 1934.
+Added: Pablo Cagnoni , our President, Research and Development , adopted a trading plan on November 20, 2025 providing for the sale of up to an aggregate of 56,002 shares of our common stock until November 20, 2026 .
During the three months ended December 31, 2025, no director or officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities, whether or not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), other than as set forth above.
2 unchanged sentences
Directors, Executive Officers and Corporate Governance
−Removed: The information required by this item (with respect to Directors) is incorporated by reference from the information under the caption “Election of Directors” contained in our Proxy Statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for our 2025 Annual Meeting of Stockholders to be held on June 10, 2025 (the “Proxy Statement”).
−Removed: Certain information required by this item concerning executive officers is set forth in Part I of this Report under the caption “Information about our Executive Officers” and is incorporated herein by reference.
−Removed: Item 405 of Regulation S-K calls for disclosure of any known late filing or failure by an insider to file a report required by Section 16(a) of the Exchange Act.
−Removed: To the extent disclosure for delinquent reports is being made, it can be found under the caption “Section 16(a) Beneficial Ownership Reporting Compliance” in the Proxy Statement and is incorporated herein by reference.
−Removed: We have adopted a Code of Business Conduct and Ethics that applies to all of our officers and employees, including our Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer, Corporate Controller and other employees who perform financial or accounting functions.
+Added: Certain information required by this item is incorporated by reference from the information under the captions “Election of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance” contained in our Proxy Statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for our 2026 Annual Meeting of Stockholders to be held on June 8, 2026 (the “Proxy Statement”).
+Added: Certain information required by this item concerning executive officers is set forth in Part I of this Annual Report on Form 10-K under the caption “Information about our Executive Officers” and is incorporated herein by reference.
+Added: We have adopted a Code of Business Conduct and Ethics that applies to all of our officers and employees, including our Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Corporate Controller and other employees who perform similar functions.
The Code of Business Conduct and Ethics sets forth the basic principles that guide the business conduct of our employees.
−Removed: We have also adopted a Senior Financial Officers’ Code of Ethics that specifically applies to our Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer, Corporate Controller, and others providing similar functions.
+Added: We have also adopted a Senior Financial Officers’ Code of Ethics that specifically applies to our Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Corporate Controller, and others providing similar functions.
Stockholders may request a free copy of our Code of Business Conduct and Ethics and our Senior Financial Officers’ Code of Ethics by contacting Incyte Corporation, Attention:
1 unchanged sentence
Our website address listed in the prior sentence and below is intended to be an inactive, textual reference only.
−Removed: None of the materials on, or accessible through, our website is part of this report or is incorporated by reference herein.
+Added: None of the materials on, or accessible through, our website are part of this report or are incorporated by reference herein.
To date, there have been no waivers under our Code of Business Conduct and Ethics or Senior Financial Officers’ Code of Ethics.
18 unchanged sentences
The information required by this item is incorporated by reference from the information under the caption “Ratification of Independent Registered Public Accounting Firm” contained in the Proxy Statement.
−Removed: Exhibits, Financial Statement Schedules
+Added: Exhibits and Financial Statement Schedules
(a) Documents filed as part of this report:
16 unchanged sentences
10.6# Form of Restricted Stock Unit Award Agreement for Outside Directors under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019).
−Removed: 10.7# F orm of U.S.
−Removed: Stock Option Agreement for Executive Officers under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan (incorporated by re ference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024).
−Removed: 10.8# F orm of U.S.
−Removed: Restricted Stock Unit Award Agreement under the Inc yte Corporat ion Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the qu arter ended September 30, 2024 ).
−Removed: 10.9# I ncyte Corporation 2024 Indu cement Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company's Registration Statement on Form S-8 (File No.
−Removed: 10.10# F o rm of Global Nonstatutory Stock Option Agreement for Executive Officers under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exh ibit 99.2 to the Company's Registration S tatement on Form S -8 (File No.
+Added: 10.7# Form of U.S.
+Added: Stock Option Agreement for Executive Officers under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024).
+Added: 10.8# Form of U.S.
+Added: Restricted Stock Unit Award Agreement under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024).
+Added: 10.9# Incyte Corporation 2024 Inducement Stock Incentive Plan, as amended June 25, 2025 (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed June 27, 2025).
+Added: 10.10# Form of Global Nonstatutory Stock Option Agreement for Executive Officers under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.2 to the Company’s Registration Statement on Form S-8 (File No.
333-277043) ) .
−Removed: 10.11# Form of Global Restricted Stock Unit Agreement under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99 .3 to the Company's Registration S tatement on Form S-8 (File No.
+Added: 10.11# Form of Global Restricted Stock Unit Agreement under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.3 to the Company’s Registration Statement on Form S-8 (File No.
333-277043) ) .
−Removed: 10.12# F orm of Performance Share Awar d Agreement under the Incyte Corp oration 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhi bit 99.4 to the Company's Registration S tatement on Form S-8 (F ile No.
+Added: 10.12# Form of Performance Share Award Agreement under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.4 to the Company’s Registration Statement on Form S-8 (File No.
+Added: 333-277043) ) .
10.13# Form of U.S.
−Removed: Nonstatutory Stock Option Agreement for Executive Officers under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended Septe mber 30, 2024).
−Removed: 10.14# F orm of U.S.
−Removed: Restricted Stock Unit Award Agreement for Executive Officers under the Incyte Corp oration 2024 Inducement Stock Incentive Plan (in corporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q for the quarter en ded September 30, 2024).
+Added: Nonstatutory Stock Option Agreement for Executive Officers under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024).
+Added: 10.14# Form of U.S.
+Added: Restricted Stock Unit Award Agreement for Executive Officers under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024).
Number Description of Document
1 unchanged sentence
10.16# 1997 Employee Stock Purchase Plan of Incyte Corporation, as amended on April 1 1 , 202 5 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed June 11 , 202 5 ).
−Removed: 10.17# Form of Employment Agreement between the Company and Barry P.
−Removed: Flannelly (effective as of August 11, 2014), Christiana Stamoulis (effective as of February 11, 2019), Steven H.
−Removed: Stein (effective as of March 2, 2015), Vijay K.
−Removed: Iyengar (effective as of May 9, 2016), Pablo J.
−Removed: Cagnoni (effective as of June 7, 2023), Sheila A.
−Removed: Denton (effective as of October 2, 2023), Matteo Trotta (effective as of March 25, 2024), Lee Heeson (effective as of October 1, 2024) and Mohamed Issa (effective as of January 6, 2025) (incorporated by reference to Exhibit 10.14 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2012).
−Removed: 10.18# Form of Amended and Restated Employment Agreement, effective as of April 18, 2012, between the Company and Paula J.
−Removed: Swain (incorporated by reference to Exhibit 10.14 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012).
−Removed: 10.19# Offer of Employment Letter, dated December 14, 2018, from the Company to Christiana Stamoulis (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019).
−Removed: 10.20# Amended and Restated Employment Agreement between the Company and Hervé Hoppenot, dated as of October 25, 2019 (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019).
+Added: 10.17# Form of Employment Agreement between the Company and Steven H.
+Added: Stein (effective as of March 2, 2015), Pablo J.
+Added: Cagnoni (effective as of June 7, 2023) , Matteo Trotta (effective as of March 25, 2024), Lee Heeson (effective as of October 1, 2024) , Mohamed Issa (effective as of January 6, 2025) , Patrick A .
+Added: Maye s ( effective as of July 21, 2025), Ramitpal K.
+Added: Basi (effective as of August 25, 2025) , David H .
+Added: Gar dner (effective as of September 22, 2025) and Richard Hoffman (effective as of December 1 , 2025) (incorporated by reference to Exhibit 10.14 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2012).
10.18# Offer of Employment Letter, dated April 21, 2023, from the Company to Pablo J.
Cagnoni (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023).
+Added: 10.19# Transition Agreement between the Company and Hervé Hoppenot , dated as of June 26, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8 - K filed June 27 , 202 5 ).
+Added: 10.20# Offer of Employment Letter, dated June 23, 2025, from the Company to William J.
+Added: Meury (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed June 27, 2025).
+Added: 10.21# Employment Agreement between the Company and William J.
+Added: Meury, dated as of June 26, 2025 (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed June 27, 2025).
+Added: 10.22# I n cyte Corporation Executive Severance Plan (incorporated by reference to Exhibit 10.
+Added: 4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 202 5 ).
10.23† Collaboration and License Agreement entered into as of November 24, 2009, by and between the Company and Novartis International Pharmaceutical Ltd.
4 unchanged sentences
(incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020).
+Added: 10.23.3†† Extension, dated as of March 12, 2025, to the Amendment, dated as of March 20, 2020, to the Collaboration and License Agreement entered into as of November 24, 2009, by and between the Company and Novartis International Pharmaceutical Ltd.
+Added: (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025).
10.24† License, Development and Commercialization Agreement, entered into as of December 18, 2009, by and between the Company and Eli Lilly and Company (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019).
3 unchanged sentences
2 on Form 10-K/A to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016).
−Removed: 10.23.4†† Letter Agreement, dated May 13, 2020, between the Company and Eli Lilly and Company, together with related Letter of Understanding, dated March 5, 2020, between the Company and Eli Lilly and Company, each relating to License, Development and Commercialization Agreement entered into as of December 18, 2009 by and between the Company and Eli Lilly and Company (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020).
Number Description of Document
−Removed: 10.24 Registration Rights Agreement, dated as of February 12, 2016, between the Company and 667, L.P., Baker Brothers Life Sciences, L.P.
−Removed: and 14159, L.P.
−Removed: (incorporated by reference to Exhibit 10.28 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2015).
+Added: 10.24.4†† Letter Agreement, dated May 13, 2020, between the Company and Eli Lilly and Company, together with related Letter of Understanding, dated March 5, 2020, between the Company and Eli Lilly and Company, each relating to License, Development and Commercialization Agreement entered into as of December 18, 2009 by and between the Company and Eli Lilly and Company (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020).
+Added: 10.24.5*†† Letter of Understanding, dated October 24, 2025, between the Company and Eli Lilly and Company, relating to the License, Development and Commercialization Agreement entered into as of December 18, 2009 by and between the Company and Eli Lilly and Company.
+Added: 10.25* Registration Rights Agreement, dated as of February 6 , 20 2 6, between the Company and 667, L.P.
+Added: and Baker Brothers Life Sciences, L.P.
10.26 Revolving Credit and Guaranty Agreement, dated as of August 18, 2021, among the Company, the guarantors party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021).
3 unchanged sentences
10.26.2 Amendment No.
−Removed: 2 , dated as of June 28, 2024, to R evolving Credit and Guar anty Agreement dated as of August 18, 2021, among the Company, the guarantors party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent (in corporated by reference to Exhibit 10.1 to the Company's Quart erly Report on Form 10-Q for the qu a rter ended June 30, 2024 ).
−Removed: 19.1* Policy on insider trading.
+Added: 2, dated as of June 28, 2024, to Revolving Credit and Guaranty Agreement dated as of August 18, 2021, among the Company, the guarantors party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024).
+Added: 19.1 Policy on insider trading (incorporated by reference to Exhibit 19.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024).
21.1* Subsidiaries of the Company.
2 unchanged sentences
31.1* Rule 13a 14(a) Certification of the Chief Executive Officer.
−Removed: 31.2* Rule 13a 14(a) Certification of the Chief Financial Officer.
+Added: 31.2* Rule 13a 14(a) Certification of the Principal Financial Officer.
32.1** Statement of the Chief Executive Officer under Section 906 of the Sarbanes Oxley Act of 2002 (18 U.S.C Section 1350).
−Removed: 32.2** Statement of the Chief Financial Officer under Section 906 of the Sarbanes Oxley Act of 2002 (18 U.S.C Section 1350).
−Removed: 97 Incyte Corporation Policy for Recoupment of Erroneously Awarded Compensation (inc orporated by reference to Exhibit 97.1 to the Company's Amended Annual Report on Form 10-K/A for the year ended December 31, 202 3 filed February 16, 2024 ) .
+Added: 32.2** Statement of the Principal Financial Officer under Section 906 of the Sarbanes Oxley Act of 2002 (18 U.S.C Section 1350).
+Added: 97 Incyte Corporation Policy for Recoupment of Erroneously Awarded Compensation (incorporated by reference to Exhibit 97.1 to the Company’s Amended Annual Report on Form 10-K/A for the year ended December 31, 2023 filed February 16, 2024).
101 XBRL Instance – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
22 unchanged sentences
INCYTE CORPORATION
−Removed: /s/ H ERVÉ H OPPENOT
−Removed: Hervé Hoppenot
+Added: February 10, 2026
+Added: /s/ WILLIAM J.
President, and Chief Executive Officer
+Added: (Principal Executive Officer)
February 10, 2026
+Added: /s/ THOMAS TRAY
+Added: Vice President and Chief Accounting Officer
+Added: (Principal Financial Officer and Principal Accounting Officer)
POWER OF ATTORNEY
−Removed: KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Hervé Hoppenot, Christiana Stamoulis, and Sheila Denton, and each of them, his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.
+Added: KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints William Meury, Thomas Tray, and Richard Hoffman, and each of them, his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature Title Date
−Removed: /s/ HERVÉ HOPPENOT
−Removed: President and Chief Executive Officer (Principal Executive Officer) and Chairman of the Board February 10, 2025
−Removed: Hervé Hoppenot
−Removed: /s/ CHRISTIANA STAMOULIS
−Removed: Executive Vice President and Chief Financial Officer (Principal Financial Officer) February 10, 2025
−Removed: Christiana Stamoulis
+Added: /s/ WILLIAM J.
+Added: President and Chief Executive Officer (Principal Executive Officer) February 10, 2026
/s/ THOMAS TRAY
−Removed: Vice President and Chief Accounting Officer (Principal Accounting Officer) February 10, 2025
+Added: Vice President and Chief Accounting Officer (Principal Financial Officer and Principal Accounting Officer) February 10, 2026
/s/ JULIAN C.
15 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.